Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 3/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12688390 | 1.00 | DRD2 (0.46) | DRD2DRD3KDM1AMAOBRORC | |
| SCHEMBL12688482 | 0.90 | RORC (0.44) | DRD2DRD3KDM1AMAOBRORC | |
| SCHEMBL12692913 | 0.86 | RORC (0.50) | RORC | |
| SCHEMBL1498399 | 0.86 | RORC (0.50) | RORC | |
| SCHEMBL1498398 | 0.86 | RORC (0.50) | RORC | |
| SCHEMBL5543212 | 0.82 | MAOB (0.52) | DRD2DRD3KDM1AMAOBCCR5 | |
| SCHEMBL5548715 | 0.82 | MAOB (0.52) | DRD2DRD3KDM1AMAOBCCR5 | |
| SCHEMBL5548711 | 0.82 | MAOB (0.52) | DRD2DRD3KDM1AMAOBCCR5 | |
| SCHEMBL12688654 | 0.80 | MAPT (0.48) | EPHX2KMT2AALDH1A1 | |
| SCHEMBL24711750 | 0.79 | EPHX2 (0.62) | RORCEPHX2KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | DRD2 1003/4885DRD3 956/4885KDM1A 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.